Biomarker-Guided Adjuvant Treatment Supports Real-World Survival in Early NSCLC
Biomarker-targeted adjuvant therapy improved survival in early-stage NSCLC, highlighting the importance of testing and reducing treatment disparities.
Read More
Ad Code: Tecentriq - Display Banners Conference - MAY - 206571
‘Spread Through Air Spaces’ Predicts Poorer Prognosis in Stage 1 EGFR-Mutant Lung Adenocarcinoma
Data from ASCO 2025 shows spread through air spaces has emerged as a powerful predictor of poor outcomes in stage 1 EGFR-mutant lung cancer, revealing aggressive molecular traits that could reshape future risk stratification and treatment decisions.
Read More
In Early NSCLC, Molecular Testing Rates Improve With EMR Nudge
An EMR-based prompt significantly boosted molecular testing rates and detection of actionable mutations in early-stage, non-squamous NSCLC post-surgery.
Read More
ASCO 2025 – eNSCLC
The latest news from ASCO 2025 focusing on eNSCLC including abstracts, features, and helpful conference information.
Read More
Early NSCLC at ASCO: Evaluating New Assay & Treatment Patterns
New ASCO data highlight presurgical ctDNA as a relapse predictor in early NSCLC and show surgery improves survival over radiation among veterans.
Read More
Which session are you most looking forward to attending at ASCO?
Share your thoughts! Which session are you most looking forward to attending at ASCO?
Read More